Ann: Quarterly report and cash flow statement for Q1 2021, page-37

I got in touch with Jon Pilcher to comment on the diarrhea problem that a patient exhibited in your post,
and this is what Jon wrote back. all looks good iMO

Hi George,

Thanks for your e-mail. The entire safety and efficacy data from 180 patients is what approval will be based on. I can’t comment on individual experiences, both positive and negative (and the participants shouldn’t comment while Lavender is still running). As you know on Thursday we released the Q1 update confirming all is on track for Q4 results and highlighting the scale of Acadia’s commitment.

Kind regards, Jon

Jon Pilcher

Chief Executive Officer

Neuren Pharmaceuticals